酪氨酸激酶抑制剂治疗晚期甲状腺癌的最新研究进展  

Progress in tyrosine kinase inhibitor treatment in advanced thyroid cancer

作　　者：何紫燕 邱娴 萨日 陈立波[1] HE Ziyan;QIU Xian;SA Ri;CHEN Libo(Department of Nuclear Medicine,Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,Shanghai 200233,China)

机构地区：[1]上海交通大学附属第六人民医院核医学科,上海200233

出　　处：《肿瘤》2022年第1期65-76,共12页Tumor

摘　　要：近年来,酪氨酸激酶抑制剂(tryosine kinase inhibitor,TKI)治疗晚期甲状腺癌显示出良好的应用前景。本文在汇总临床试验数据的基础上,介绍了最新真实世界研究的结果,探讨了TKI治疗晚期甲状腺癌的疗效、安全性以及预后相关因素,总结了常见的不良反应以及咯血、中性粒细胞减少、气管食管瘘、脓胸和急性胰腺炎等罕见的不良反应。就TKI治疗晚期甲状腺癌的最佳启动时机而言,目前尚无定论,但预后研究提示在肿瘤负荷过大或肿瘤相关症状占主导地位之前,开始TKI治疗可能更为合适。In recent years,tryosine kinase inhibitor(TKI)has shown great promising in advanced thyroid cancer.Based on the data of clinical trials,the newest real-world studies which reveal the efficacy,safety and prognostic factors for TKI in patients with advanced thyroid cancer is reviewed.Besides some common adverse events,some rare adverse events are also summarized,such as hemoptysis,neutropenia,tracheoesophageal fistula,empyema,and acute pancreatitis.Optimal timing of TKI has been equivocal.It may be appropriate to start TKI therapy before a high tumor burden and tumor-related symptoms according to the analysis of predictors.

关 键 词：甲状腺癌 酪氨酸激酶抑制剂 疗效 安全性 治疗时机 

分 类 号：R736.1[医药卫生—肿瘤]